echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In 2020, the wave of restructuring and restructuring of pharmaceutical companies and layoffs will continue to emerge

    In 2020, the wave of restructuring and restructuring of pharmaceutical companies and layoffs will continue to emerge

    • Last Update: 2020-11-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" Recently, Takeda Pharmaceuticals announced that it will recruit early-retirement employees in its domestic division between September 28 and October 16.
    this recruitment is mainly for sales and administrative departments, not for research and development and manufacturing departments, employees who have worked continuously for more than 3 years and have reached the age of 30 can apply, but the specific number of recruitment has not been made public.
    the move is said to be part of a personnel reform by Takeda Pharmaceuticals for the future.
    for employees who retire early, Takeda will support their re-employment in addition to a special weighted pension.
    in fact, Takeda has been selling non-core assets since 2019, making sweeping changes.
    industry believes this is mainly related to Takeda's $59bn acquisition of Shire last year.
    , in addition to Takeda Pharmaceuticals, more and more multinational pharmaceutical companies in recent years have begun to play the "return to the core business" slogan.
    Since 2018, Bayer, Pfizer, GSK, Merca East and other multinational pharmaceutical companies have split, divested, shut down pipelines and even large-scale layoffs and other "big-money" adjustments, the trend has increased since 2020.
    it is understood that the first to announce a split plan in the first half of 2020 is Mercedon.
    February, Mercadon announced that it would begin divesting its women's health products, mature products and biosimilar products in 2020, created a new independent public company.
    will retain products with key growth points, such as tumors, vaccines, in-hospital products and animal health.
    Same month, GSK also announced a two-year spin-off that would split into two separate companies, a biopharmaceutical company focused on genes and new technologies for research and development in immune system-related science, and another in consumer health.
    July, Sanofi, the French pharmaceutical company, announced plans to cut 1,700 jobs in Europe, including about 1,000 in France over the next three years, or an average of about 350 a year.
    that Sanofi currently employs about 25,000 people in France.
    In fact, in addition to multinational enterprises, into 2020, under the influence of consistent evaluation, volume procurement and other policies, China's pharmaceutical enterprises are also moving from generic drugs to high-end generic drugs, innovative drugs, personnel changes, especially high-end talent changes are becoming the trend.
    understood that in the first half of this year, there have been more than 100 listed pharmaceutical executives change positions.
    And since July 2020 alone, 36 senior executives of listed companies in the biopharmaceutical sector have resigned, including 10 positions as deputy general managers, involving Jiangsu Hengrui, Gan Li Pharmaceuticals, Fosun Pharma, Junshi Bio and other well-known pharmaceutical companies.
    pharmaceutical companies frequently make layoffs, restructuring and transformation of the move? The industry believes that pharmaceutical companies, especially multinational pharmaceutical companies are generally affected by the pharmaceutical environment, pharmaceutical policies, after all, they "lie down to make money" the good days have passed.
    , for example, Novart responded to the media last year by saying that its job cuts would be completed by mid-2022 and that the job cuts would help streamline its organizational structure and focus resources on innovative research and development.
    , domestic pharmaceutical companies in the pharmaceutical landscape changes, but also urgently need to transform and upgrade.
    Industry insiders said that in the consistent evaluation, health care fees, volume procurement and other policies, the generic drug industry is facing a cold winter, conservative estimates, at least one-third of domestic pharmaceutical companies will face closure, the rest of the drug companies need to undergo a more rigorous test.
    In short, the current pharmaceutical landscape is changing inevitably, as large pharmaceutical companies continue to focus on the company's key business and innovative drug channels, to consolidate market position, its restructuring, splitting, is bound to continue to affect the global pharmaceutical landscape.
    Against this background, domestic pharmaceutical companies need to adjust their talent structure according to market trends and their own needs, and under the background that innovative drugs and high-end generic drugs have become the new research and development direction, pharmaceutical companies need to accelerate the recruitment and training of high-level personnel who are really needed by pharmaceutical companies to become the main force in the development of domestic pharmaceutical enterprises.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.